Clinical Trial Update: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for DT388IL3 fusion protein in acute myeloid leukemia and myelodysplastic syndromes (Phase 1/2) completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Myelodysplastic Syndrome

Drugs mentioned

• DT388IL3 fusion protein (DT388IL3)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-04-23